ScinoPharm Taiwan, Ltd. · TWSE:1789
ScinoPharm Taiwan — Investor Presentation (October 2015)
27 slides from ScinoPharm Taiwan's investor presentation, Oct 8, 2015
Slide 1: ScinoPharm Management Presentation
TWSE 1789 ScinoPharm Management Presentation 1
Slide 2: Disclaimer
Disclaimer This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”). Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein.
Slide 3: Table of Content
Confidential Table of Content Overview of ScinoPharm ScinoPharm’s Strategies and Opportunities Operating Results & Outlook 3 3
Slide 4: Overview of ScinoPharm - an API + ANDA Company
Overview of ScinoPharm - an API + ANDA Company Active Pharmaceutical Ingredients Abbreviated New Drug Application
Slide 5: Background
Background Established in 1997 in Taiwan and listed on TWSE in 2011, current market cap around US$830 million Major shareholders include Uni-President Group, National Development Fund, Taiwan Sugar, etc. Facility & organization built in Taiwan by experienced Syntex team, received multiple regulatory
Slide 6: World Class API Facilities
World Class API Facilities Taiwan China 6.6 hectares of land, 330K sqft facilities with 6.6 hectares of land with ~250M3 reactor volume >200M3 reactor volume 2 of 8 production lines equipped with high potency 8 of 18 production lines equipped with high potency capabilities for cytotoxics capabilitie
Slide 7: Business Overview
Confidential Business Overview Risk & return balanced model to offer APIs and fill/finish capability for both generic and new drugs 70 generic APIs developed with 27 APIs launched; 50 US DMFs filed (711 DMFs WW), 24 US DMFs in oncological APIs 80+ NCE CRAM projects, with 5 launched and 7 in phase II
Slide 8: Strong Generics Product Portfolio
Confidential Strong Generics Product Portfolio 8 8 11
Slide 9: Sales Breakdowns
Confidential By Indication Sales Breakdowns By Business By Region Generic 77% 1H 2015 9 9
Slide 10: Oncology as Worldwide Top Therapy
Confidential Oncology as Worldwide Top 1 Therapy Source: Evaluate Pharma 10 19
Slide 11: ScinoPharm – Global Oncological API Leader
Confidential ScinoPharm – Global Oncological API Leader 11
Slide 12: Targeted Therapy Dominates Oncology
Confidential Targeted Therapy Dominates Oncology Supportive care 1% Protein Kinase Immunotherapy Inhibitor 23% Targeted 60% therapy Hormonal therapy 60% 14% mAb 20% ADC 11% Chemotherapy 2% Source: 2020 Sales Forecast, Global Data Others 9% 12 24
Slide 13: ScinoPharm Pipeline Echoes Therapy Trend
Confidential ScinoPharm Pipeline Echoes Therapy Trend Supportive Genito Urinary System & Ophthalmology Hematological care 5% Sex Hormones 2% 2% disorder 2% Respiratory 4% Gastrointestinal 5% Hormonal therapy Infectious disease 8% Oncology 21% 36% Cadiovascular 8% Targeted therapy Immunology 74% 10%
Slide 14: Diversified CRAM Portfolio
Confidential Diversified CRAM Portfolio Stage First Launch Year Indication Location Commercial 2005 Eluting Stent US Commercial 2009/2013 Skin Infection/HAP US/EU Commercial 2011 Depression US Commercial 2012 Obesity US Commercial 2013 Seizure US Stage Est. NDA Filing Year Indication Location Phase
Slide 15: Strategic Alliances for Formulation
Strategic Alliances for Formulation * Already launched Launch Partner Product Indications Region Remarks Year(E) 1st co-developed formulation product Genovate Entecavir Hepatitis B Viral Taiwan 2013* launch Oncological 1st US ANDA filing to trigger US FDA Sagent Myeloid Leukemia US 2016 Injectable i
Slide 16: ScinoPharm's Strategies and Opportunities
ScinoPharm’s Strategies and Opportunities
Slide 17: Long Term Strategies
Confidential Long Term Strategies Transforming to a full-scope pharma company per our core competency of R&D and cGMP manufacturing in high-technical barrier APIs Vertical Integration to Generic Formulations: Developing dossiers per our difficult-to-make APIs to increase value proposition in the sup
Slide 18: Keys to Generic Formulation Business
Keys to Generic Formulation Business Expanding formulation portfolio: Two US ANDA filed Building on-site oncological injectable facility and establishing a complete supply chain Acquiring critical resources via M&A Sustaining B2B model, promoting our formulations via strategic alliance, especially i
Slide 19: Golden Opportunities in China
Confidential Golden Opportunities in China Government’s strong support carrying into 13th five-year plan to encourage pharma industry’s CAGR of 20% Tighten GMP requirements to align with US/EU Motivate drug makers to improve quality by applying for US ANDAs, which need SPT’s world class APIs MNCs an
Slide 20: Policy Reforms to Expedite Drug Approvals
Policy Reforms to Expedite Drug Approvals Redefine new drugs and generics in China Elevate the overall quality and efficacy requirements of submissions Encourage innovative drugs via fast track approval Allow new drug developers to own drug licenses without manufacturing sites Clear the application
Slide 21: Operating Results & Outlook
Operating Results & Outlook
Slide 22: Half Year P&L - Consolidated
Half Year P&L - Consolidated 1H,’15 1H,’14 In NT$ million, except for EPS YoY (Reviewed) (Reviewed) Net Sales 1,942 2,245 -13% Gross Profit 709 933 -24% Gross margin 37% 42% Operating Expenses (442) (538) -18% Operating Income 267 395 -32% Operating margin 14% 18% Other Rev.(Exp.) 99 2 4850% Net Inc
Slide 23: Balance Sheet - Consolidated
Balance Sheet - Consolidated 2015/6/30 2014/6/30 In NT$ million (Reviewed) (Reviewed) Cash and Cash Equivalents 2,410 20% 2,184 18% Accounts Receivable 568 5% 793 7% Inventories 2,315 19% 2,676 23% Long-Term Investments 339 3% 255 2% Property, plant & equipment 5,142 43% 4,658 40% Other assets 1,100
Slide 24: Cash Flows - Consolidated
Cash Flows - Consolidated 1H 2015 1H 2014 In NT$ million (Reviewed) (Reviewed) Cash and cash equivalents at 1,928 2,289 beginning of period Cash flows from operating activities 589 248 CAPEX (345) (694) Short-term borrowings 212 317 Others 26 24 Cash and cash equivalents at 2,410 2,184 end of period
Slide 25: 2015 Product Launch Plan
2015 Product Launch Plan API Region Indications Brand Marketer Regional Sales WW Sales Azacitidine US MDS Oncology Celgene US$323MM* US$815MM* Benazepril CN Hypertension, CV Novartis US$65MM** US$480MM* Desmopressin US Polyuria Ferring US$131MM* US$395MM* Letrozole JP Breast Cancer Novartis US$51MM*
Slide 26: Pipeline Outlook
Pipeline Outlook 4-5 new launches 5-6 new launches 5-6 new launches 1st co-developed US 1st home-made drug US 3 drug products launched in China ANDA launched ANDA filing 1st home-made drug launched in US 2015 2016 2017 2018 2019 2020 3-5 new launches 4-5 new launches 6-8 new launches SPC US FDA insp
Slide 27: Brand Quality with Asian Advantages
Confidential Brand Quality with Asian Advantages www.scinopharm.com 27
ScinoPharm Taiwan — Investor Presentation (October 2015) on 6ix